metformin and Lupus Nephritis
metformin has been researched along with Lupus Nephritis in 4 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Lupus Nephritis: Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
" This research used in vivo and in vitro experiments to explore the therapeutic potential of metformin in kidney injury from LN-induced inflammation." | 4.12 | Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway. ( An, N; Chen, XC; Huang, LF; Huang, XR; Li, HY; Liu, HF; Liu, ZJ; Lu, X; Pan, QJ; Su, HY; Wu, D; Wu, HL; Yang, C; Zhu, SP, 2022) |
Research
Studies (4)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Chen, XC | 1 |
Wu, D | 1 |
Wu, HL | 1 |
Li, HY | 1 |
Yang, C | 1 |
Su, HY | 1 |
Liu, ZJ | 1 |
Huang, XR | 1 |
Lu, X | 1 |
Huang, LF | 1 |
Zhu, SP | 1 |
Pan, QJ | 1 |
An, N | 1 |
Liu, HF | 1 |
Cornaby, C | 1 |
Elshikha, AS | 1 |
Teng, X | 1 |
Choi, SC | 1 |
Scindia, Y | 1 |
Davidson, A | 1 |
Morel, L | 1 |
Peng, X | 1 |
Yang, T | 1 |
Liu, G | 1 |
Liu, H | 1 |
Peng, Y | 1 |
He, L | 1 |
Wang, H | 1 |
Li, T | 1 |
Chen, S | 1 |
Gu, Y | 1 |
Ye, S | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus[NCT02741960] | Phase 4 | 180 participants (Actual) | Interventional | 2016-05-24 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
1 trial available for metformin and Lupus Nephritis
Article | Year |
---|---|
Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Arthritis, Rheumatoid; Autoantibodies; Case-Control Stud | 2015 |
Other Studies
3 other studies available for metformin and Lupus Nephritis
Article | Year |
---|---|
Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway.
Topics: AMP-Activated Protein Kinases; Animals; Humans; Inflammation; Kidney; Lipopolysaccharides; Lupus Ery | 2022 |
Efficacy of the Combination of Metformin and CTLA4Ig in the (NZB × NZW)F1 Mouse Model of Lupus Nephritis.
Topics: Abatacept; Animals; Antigens, CD; Autoantibodies; CD4-Positive T-Lymphocytes; CTLA-4 Antigen; Diseas | 2020 |
Piperine ameliorated lupus nephritis by targeting AMPK-mediated activation of NLRP3 inflammasome.
Topics: Alkaloids; AMP-Activated Protein Kinase Kinases; Animals; Anti-Inflammatory Agents; Benzodioxoles; C | 2018 |